Tag: Immune checkpoint inhibitors

Endocrine-related adverse events are among the most common complications of immune checkpoint inhibitor (ICI) therapy, occurring in approximately 10% of patients. These immune-related side effects can impact hormone-producing glands throughout the body, necessitating careful monitoring and management alongside a patient's cancer treatment.

Myocarditis, an inflammation of the heart muscle, is the most common and most lethal cardiovascular adverse event linked to immune checkpoint inhibitor (ICI) therapy, with some estimates reporting mortality rates as high as 50%. Understanding what is the most common manifestation of cardiotoxicity associated with immune checkpoint inhibitors is critical for early detection and improving patient outcomes.

Statin-induced autoimmune myositis is a rare condition with an estimated prevalence of 1 in 100,000 people [1.3.2]. A wide range of drugs beyond statins can also lead to muscle inflammation. Understanding what medication causes myositis is key to diagnosis and management.

According to the National Cancer Institute, immunotherapy can be administered in several ways, and the method often depends on the specific drug and cancer type. This guide will explain precisely how is targeted immunotherapy given, covering the different administration routes and what patients can expect during treatment.

According to the Endocrine Society, suppression of the hypothalamic-pituitary-adrenal (HPA) axis is an inevitable effect of chronic exogenous glucocorticoid therapy. Understanding **what medications can cause adrenal insufficiency** is critical for patient safety, as it involves a variety of drug classes that can disrupt the body's delicate hormonal balance.

Studies show immune checkpoint inhibitors are linked to a rare but severe risk of developing myasthenia gravis, with a high mortality rate in some cases involving overlapping myositis. Understanding **what drugs induce myasthenia gravis** is therefore critical for both patients and clinicians to mitigate risks and recognize symptoms early.

Affecting approximately 1% of the population, hyperthyroidism can be triggered by various factors, including certain medical treatments. For both patients and healthcare providers, it is crucial to understand **what medications can cause hyperthyroidism** and the diverse mechanisms that lead to this adverse effect.